Bradley Monk was named medical director of late-phase clinical research at Florida Cancer Specialists & Research Institute, LLC. Monks plans to leverage his experience and leadership across all tumor types as FCS expands in footprint in late-phase practice changing clinical trials.
FDA issued a draft guidance for industry that, when finalized, will provide sponsors with recommendations for conducting multiregional clinical trials in support of applications for drugs intended to treat cancer.
